Folgen
Thomas Van den Broeck
Thomas Van den Broeck
GZA Hospitals Antwerp
Keine bestätigte E-Mail-Adresse
Titel
Zitiert von
Zitiert von
Jahr
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, J Bellmunt, M Bolla, E Briers, MG Cumberbatch, M De Santis, ...
European urology 71 (4), 618-629, 2017
35902017
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers, T Van den Broeck, ...
European urology 79 (2), 243-262, 2021
19492021
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers, T Van den Broeck, ...
European urology 79 (2), 263-282, 2021
7692021
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ...
Nature genetics 50 (7), 928-936, 2018
7602018
The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review
N Fossati, PPM Willemse, T Van den Broeck, RCN van den Bergh, ...
European urology 72 (1), 84-109, 2017
4692017
Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review
T Van den Broeck, RC Van Den Bergh, N Arfi, T Gross, L Moris, E Briers, ...
European urology 75 (6), 967-987, 2019
3852019
What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the …
PC Moldovan, T Van den Broeck, R Sylvester, L Marconi, J Bellmunt, ...
European urology 72 (2), 250-266, 2017
3822017
EAU–ESTRO–ESUR–SIOG guidelines on prostate cancer
N Mottet, J Bellmunt, E Briers, M Bolla, L Bourke, P Cornford, M De Santis, ...
European Association of Urology, 2018
3662018
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ...
Nature genetics 53 (1), 65-75, 2021
2972021
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
JP Droz, M Aapro, L Balducci, H Boyle, T Van den Broeck, P Cathcart, ...
The lancet oncology 15 (9), e404-e414, 2014
2602014
Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review
M Lardas, M Liew, RC van den Bergh, M De Santis, J Bellmunt, ...
European urology 72 (6), 869-885, 2017
2562017
EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international …
TBL Lam, S MacLennan, PPM Willemse, MD Mason, K Plass, R Shepherd, ...
European urology 76 (6), 790-813, 2019
2092019
Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations
T Van den Broeck, RCN van den Bergh, E Briers, P Cornford, ...
European urology focus 6 (2), 231-234, 2020
1652020
Androgen receptor antagonists for prostate cancer therapy
C Helsen, T Van den Broeck, A Voet, S Prekovic, H Van Poppel, S Joniau, ...
Endocrine-related cancer 21 (4), T105-T118, 2014
1592014
Emerging mechanisms of enzalutamide resistance in prostate cancer
F Claessens, C Helsen, S Prekovic, T Van den Broeck, L Spans, ...
Nature reviews urology 11 (12), 712-716, 2014
1422014
Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review
L Moris, MG Cumberbatch, T Van den Broeck, G Gandaglia, N Fossati, ...
European urology 77 (5), 614-627, 2020
1382020
The effect of F877L and T878A mutations on androgen receptor response to enzalutamide
S Prekovic, ME van Royen, ARD Voet, B Geverts, R Houtman, D Melchers, ...
Molecular cancer therapeutics 15 (7), 1702-1712, 2016
1002016
Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review
RCN van den Bergh, NJ van Casteren, T Van den Broeck, ER Fordyce, ...
European urology 69 (5), 802-820, 2016
1002016
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
T Dadaev, EJ Saunders, PJ Newcombe, E Anokian, DA Leongamornlert, ...
Nature communications 9 (1), 2256, 2018
992018
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making
T Van den Broeck, S Joniau, L Clinckemalie, C Helsen, S Prekovic, ...
BioMed research international 2014, 2014
712014
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20